Sirtex is a rapidly growing, profitable, global life-sciences business focused on helping medical professionals improve clinical outcomes for cancer patients through innovative and effective interventional oncology therapies. Our current main product is a targeted radiation therapy for liver cancer called SIR-Spheres microspheres. We currently employ more than 250 people worldwide in a range of management, administration, clinical research, medical marketing, sales and manufacturing roles. Our corporate head office is based in Sydney, Australia with regional headquarters in Boston USA, Bonn, Germany and Singapore. Together the team at Sirtex is challenging established practices and introducing innovative new therapies that promise to improve the lives of people around the world facing the challenges of cancer. Our ongoing success is based on our commitment to serving our medical customers, professionalism, a collaborative working culture, an entrepreneurial spirit, continuous improvement and innovation. We are dedicated to making Sirtex a great place to work and providing all our employees with a range of benefits, programs and services to ensure they have the opportunity to contribute to the success of our business and further their professional careers. We are an equal opportunity employer. SIR-Spheres¬ is a registered trademark of Sirtex SIR-Spheres Pty Ltd.